Horizon

Horizon

The purpose of the study is to assess the impact of lipoprotein (a) lowering with TQJ230 (Pelacarsen) on major cardiovascular events in patients with established cardiovascular disease. 

Please use this link for further information:

Primary Investigator: Dean Kereiakes

Follow up only

Disclaimer: Patients must have an existing, documented diagnosis to be entered into some trials.
Copyright © 2024 All rights reserved.

Web Design by TBH Creative